Hutchison China Meditech Limited Directors' Share Dealing (4126O)
18 August 2017 - 7:50PM
UK Regulatory
TIDMHCM
RNS Number : 4126O
Hutchison China Meditech Limited
18 August 2017
Directors' Share Dealing
London: Friday, August 18, 2017: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications
that:-
(a) Mr Simon To, Executive Director and Chairman, through
Wencheng Capital Limited ("WCL"), a person closely associated
("PCA") with Mr To, purchased a total of 4,900 American Depositary
Shares of the Company ("ADSs", each representing one half of one
ordinary share of US$1.00 each in the capital of Chi-Med) on August
15, 2017 at a price of US$24.50 per ADS. WCL is controlled by the
trustee of Wencheng Trust ("WT") which has been established for the
benefit of Mr To's family member, of which Mr To is the settlor;
and
(b) Ms Edith Shih, Non-executive Director and Company Secretary,
purchased a total of 5,336 ADSs at an average price of US$24.92 per
ADS on August 16 and 17, 2017.
Following the above purchases, (i) Mr To is interested in
118,489 ADSs (in Dynamic Drive Trust ("DDT") and WT of which his
family members are the beneficiaries) and 180,000 Ordinary Shares
(including the holding of 78,000 Ordinary Shares in DDT of which
his family members are the beneficiaries), representing in
aggregate approximately 0.39% of the current issued share capital
of Chi-Med; and (ii) Ms Shih is interested in 96,000 ADSs and
70,000 Ordinary Shares, representing approximately 0.19% of the
current issued share capital of Chi-Med.
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation.
(a) Wencheng Capital Limited
1 Details of the person discharging managerial responsibilities/person closely associated
----- ---------------------------------------------------------------------------------------------------------------
a) Name Wencheng Capital Limited
----- ------------------------------------ -------------------------------------------------------------------------
2 Reason for the notification
----- ---------------------------------------------------------------------------------------------------------------
a) Position/status Person closely associated with Mr Simon To, Executive Director and
Chairman. Wencheng Capital
Limited is controlled by the trustee of Wencheng Trust which has been
established for the
benefit of Mr To's family members, of which Mr To is the settlor.
----- ------------------------------------ -------------------------------------------------------------------------
b) Initial notification/Amendment Initial notification
----- ------------------------------------ -------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----- ---------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
----- ------------------------------------ -------------------------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
----- ------------------------------------ -------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----- ---------------------------------------------------------------------------------------------------------------
a) Description of the financial ADS each representing one half of one Ordinary Share of US$1.00
instrument, type of instrument ADS ISIN: US44842L1035
Identification code
----- ------------------------------------ -------------------------------------------------------------------------
b) Nature of the transaction Acquisition of 4,900 ADSs in the name of Wencheng Capital Limited which
holds the ADSs for
a family trust (Wencheng Trust) of which Mr To is the settlor on August
15, 2017 at a price
of US$24.50 per ADS.
----- ------------------------------------ -------------------------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
----- ------------------------------------ ------------------------------------ -----------------------------------
US$24.50 4,900
------------------------------------------------------------------------------- -----------------------------------
d) Aggregated information N/A
- Aggregated volume
- Price
----- ------------------------------------ -------------------------------------------------------------------------
e) Date of the transaction 2017-08-15
----- ------------------------------------ -------------------------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
----- ------------------------------------ -------------------------------------------------------------------------
(b) Ms Edith Shih
1 Details of the person discharging managerial responsibilities/person closely associated
----- ---------------------------------------------------------------------------------------------------------------
a) Name Ms Edith Shih
----- ------------------------------------ -------------------------------------------------------------------------
2 Reason for the notification
----- ---------------------------------------------------------------------------------------------------------------
a) Position/status Non-executive Director and Company Secretary
----- ------------------------------------ -------------------------------------------------------------------------
b) Initial notification/Amendment Initial notification
----- ------------------------------------ -------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
----- ---------------------------------------------------------------------------------------------------------------
a) Name Hutchison China MediTech Limited
----- ------------------------------------ -------------------------------------------------------------------------
b) LEI 2138006X34YDQ6OBYE79
----- ------------------------------------ -------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
----- ---------------------------------------------------------------------------------------------------------------
a) Description of the financial ADS each representing one half of one Ordinary Share of US$1.00
instrument, type of instrument ADS ISIN: US44842L1035
Identification code
----- ------------------------------------ -------------------------------------------------------------------------
b) Nature of the transaction Acquisition of 5,336 ADSs on August 16 and 17, 2017 at an average price
of US$24.92 per ADS.
----- ------------------------------------ -------------------------------------------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
----- ------------------------------------ ------------------------------------ -----------------------------------
US$24.73 1,000
------------------------------------------------------------------------------- -----------------------------------
US$24.74 300
------------------------------------------------------------------------------- -----------------------------------
US$24.75 802
------------------------------------------------------------------------------- -----------------------------------
US$24.80 400
------------------------------------------------------------------------------- -----------------------------------
US$24.79 31
------------------------------------------------------------------------------- -----------------------------------
US$25.08 1,748
------------------------------------------------------------------------------- -----------------------------------
US$25.07 300
------------------------------------------------------------------------------- -----------------------------------
US$25.06 52
------------------------------------------------------------------------------- -----------------------------------
US$25.09 703
------------------------------------------------------------------------------- -----------------------------------
d) Aggregated information Aggregated volume: 5,336 ADSs
- Aggregated volume Price information: US$24.92
- Price
----- ------------------------------------ -------------------------------------------------------------------------
e) Date of the transaction 2017-08-16 - acquisition of 2,533 ADSs
2017-08-17 - acquisition of 2,803 ADSs
----- ------------------------------------ -------------------------------------------------------------------------
f) Place of the transaction Nasdaq Stock Market
----- ------------------------------------ -------------------------------------------------------------------------
About Chi-Med
Chi-Med is an innovative biopharmaceutical company which
researches, develops, manufactures and sells pharmaceuticals and
healthcare products. Its Innovation Platform, Hutchison MediPharma
Limited, focuses on discovering and developing innovative
therapeutics in oncology and autoimmune diseases for the global
market. Its Commercial Platform manufactures, markets, and
distributes prescription drugs and consumer health products in
China.
Chi-Med is majority owned by the multinational conglomerate CK
Hutchison Holdings Limited ("CK Hutchison") (SEHK: 0001). For more
information, please visit: www.chi-med.com.
CONTACTS
Investor Enquiries
Mark Lee,
SVP Corporate Finance & Development +852 2121 8200
U.K. & International Media Enquiries
Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk
U.S. Based Media Enquiries
Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com
Investor Relations
Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk
Panmure Gordon (UK) Limited
Richard Gray / Andrew Potts +44 (20) 7886 2500
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLIFVATAITLID
(END) Dow Jones Newswires
August 18, 2017 05:50 ET (09:50 GMT)
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From Apr 2024 to May 2024
Hutchmed (china) (LSE:HCM)
Historical Stock Chart
From May 2023 to May 2024